Pitfalls and Considerations in Determining the Potency and Mutant Selectivity of Covalent Epidermal Growth Factor Receptor Inhibitors.

MLA

Hoyt, Kristopher W., et al. “Pitfalls and Considerations in Determining the Potency and Mutant Selectivity of Covalent Epidermal Growth Factor Receptor Inhibitors.” Journal of Medicinal Chemistry, vol. 67, no. 1, Jan. 2024, pp. 2–16. EBSCOhost, https://doi.org/10.1021/acs.jmedchem.3c01502.

APA

Hoyt, K. W., Urul, D. A., Ogboo, B. C., Wittlinger, F., Laufer, S. A., Schaefer, E. M., May, E. W., & Heppner, D. E. (2024). Pitfalls and Considerations in Determining the Potency and Mutant Selectivity of Covalent Epidermal Growth Factor Receptor Inhibitors. Journal of Medicinal Chemistry, 67(1), 2–16. https://doi.org/10.1021/acs.jmedchem.3c01502

Chicago

Hoyt, Kristopher W, Daniel A Urul, Blessing C Ogboo, Florian Wittlinger, Stefan A Laufer, Erik M Schaefer, Earl W May, and David E Heppner. 2024. “Pitfalls and Considerations in Determining the Potency and Mutant Selectivity of Covalent Epidermal Growth Factor Receptor Inhibitors.” Journal of Medicinal Chemistry 67 (1): 2–16. doi:10.1021/acs.jmedchem.3c01502.